Cargando…
The Black Hole: CAR T Cell Therapy in AML
SIMPLE SUMMARY: Unlike B cell malignancies, the progress on generating an adoptive T cell therapy for relapsed/refractory acute myeloid leukemia (AML) remains insufficient. This review focuses on the main challenges in the field and novel strategies to overcome them. ABSTRACT: Despite exhaustive stu...
Autores principales: | Atilla, Erden, Benabdellah, Karim |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216020/ https://www.ncbi.nlm.nih.gov/pubmed/37345050 http://dx.doi.org/10.3390/cancers15102713 |
Ejemplares similares
-
Resistance against anti-CD19 and anti-BCMA CAR T cells: Recent advances and coping strategies
por: Atilla, Pinar Ataca, et al.
Publicado: (2022) -
Biomarkers as targets for CAR-T/NK cell therapy in AML
por: Shao, Ruonan, et al.
Publicado: (2023) -
Emerging CAR T Cell Strategies for the Treatment of AML
por: Vishwasrao, Paresh, et al.
Publicado: (2022) -
Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML)
por: Hofmann, Susanne, et al.
Publicado: (2019) -
Recent Advances in the Development of Anti-FLT3 CAR T-Cell Therapies for Treatment of AML
por: Pedersen, Maya Graham, et al.
Publicado: (2022)